Povorcitinib EU approval for HS expands Incyte's dermatology portfolio, but revenue impact uncertain
Read source articleWhat happened
Incyte announced European approval of povorcitinib (Povofortay) as the first once-daily oral treatment for adults with moderate to severe hidradenitis suppurativa, a chronic inflammatory skin condition with limited oral options. This approval comes ahead of the expected U.S. approval in early 2027 and adds a new product to Incyte's non-Jakafi franchise, complementing Opzelura and oncology assets. The approval strengthens the diversification thesis but does not eliminate the company's heavy reliance on Jakafi, which still generated $3.09 billion in 2025 versus Opzelura's $678.5 million. European pricing and reimbursement will be key, as oral convenience must compete against established injectable biologics from AbbVie and Novartis. Initial launch traction and market share will determine whether povorcitinib becomes a meaningful contributor before Jakafi's patent cliff in 2028.
Implication
The approval de-risks the povorcitinib program and adds a new revenue stream, but European launches often face slower uptake due to country-by-country reimbursement negotiations. The competitive landscape includes injectable biologics with established efficacy and safety profiles, so povorcitinib must differentiate on convenience and price. Investors should track initial sales and market share in key EU markets over the next few quarters to gauge commercial traction. This event supports the non-Jakafi growth story but does not change the fundamental need for multiple products to scale significantly before 2028. Overall, the approval is a positive milestone but not a game-changer for the investment thesis, which still hinges on Opzelura demand acceleration and broader portfolio execution.
Thesis delta
The European approval of povorcitinib provides incremental evidence that Incyte's pipeline can deliver new products, modestly improving the diversification outlook. However, the core investment thesis remains unchanged: the stock is a WAIT as the market already prices in near-term catalysts, and the next 6-12 months are critical for proving durable demand-led growth in Opzelura and other non-Jakafi products. The approval is positive but not sufficient to warrant a rating upgrade.
Confidence
High